[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"tldr","before":"\"The most common breast cancer, driven by oestrogen. Treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs.\"","after":"\"HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs.\""}]},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","commit":"cebb34a709","date":"2026-09-08","author":"Jude Gomila","message":"Guideline mapping on every standard-of-care row; sourced biomarker prevalence for 59 targets; GuidelineChip, PrevalenceTable, CancerPrevalen","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"standardOfCare","before":"[\n      { setting: \"Early stage\", approach: \"Surgery, radiation, endocrine therapy 5-10 years; chemotherapy if genomic risk high; abemaciclib or ribociclib adjuvant for high-risk.\", refs: [\"oncotype-dx\", \"abemaciclib\"...","after":"[\n      { setting: \"Early stage\", approach: \"Surgery, radiation, endocrine therapy 5-10 years; chemotherapy if genomic risk high; abemaciclib or ribociclib adjuvant for high-risk.\", refs: [\"oncotype-dx\", \"abemaciclib\"..."}]},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","commit":"815a2a8bae","date":"2026-09-05","author":"Jude Gomila","message":"OnCo: open map of oncology — corpus (642 objects, 14 kinds), graph, static site, API, TNBC spike","file":"src/data/cancers.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"group"},{"field":"wikipedia"},{"field":"burden"},{"field":"tldr"},{"field":"summary"},{"field":"subtypes"},{"field":"biomarkers"},{"field":"standardOfCare"},{"field":"stateOfArt"},{"field":"history"},{"field":"pipeline"},{"field":"openProblems"},{"field":"targets"},{"field":"technologies"},{"field":"pathways"},{"field":"tags"}]}]